CO6341484A2 - Citoblastos para uso terapéutico que se derivan de monocitos humanos, y método para inducir los mismos - Google Patents
Citoblastos para uso terapéutico que se derivan de monocitos humanos, y método para inducir los mismosInfo
- Publication number
- CO6341484A2 CO6341484A2 CO11074347A CO11074347A CO6341484A2 CO 6341484 A2 CO6341484 A2 CO 6341484A2 CO 11074347 A CO11074347 A CO 11074347A CO 11074347 A CO11074347 A CO 11074347A CO 6341484 A2 CO6341484 A2 CO 6341484A2
- Authority
- CO
- Colombia
- Prior art keywords
- cytoblasts
- derived
- monocytes
- monocits
- induce
- Prior art date
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
- 239000003814 drug Substances 0.000 abstract 3
- 210000001616 monocyte Anatomy 0.000 abstract 3
- 210000004027 cell Anatomy 0.000 abstract 2
- 238000002659 cell therapy Methods 0.000 abstract 2
- 239000003795 chemical substances by application Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 238000012258 culturing Methods 0.000 abstract 1
- 230000032459 dedifferentiation Effects 0.000 abstract 1
- 150000002270 gangliosides Chemical class 0.000 abstract 1
- 239000001963 growth medium Substances 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000000056 organ Anatomy 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 210000001519 tissue Anatomy 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/193—Colony stimulating factors [CSF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0645—Macrophages, e.g. Kuepfer cells in the liver; Monocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/70—Undefined extracts
- C12N2500/76—Undefined extracts from plants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Cardiology (AREA)
- Rheumatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
Abstract
La presente invención se relaciona con citoblastos obtenidos al cultivar monocitos en la presencia de (i) M-CSF y (ii) por lo menos un miembro seleccionado del grupo que consiste de gangliósido y extracto derivado de planta soluble en agua, des diferenciando por lo tanto los monocitos; un agente terapéutico para tratar células, tejidos u órganos dañados; un agente de fármaco para terapia celular: un método para producir citoblastos, un medio de cultivo para des diferenciar monocitos; un agente que induce la des diferenciación; un equipo de fármaco de terapia celular; un equipo para producir células des diferenciadas; y una composición farmacéutica.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2008299359 | 2008-11-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
CO6341484A2 true CO6341484A2 (es) | 2011-11-21 |
Family
ID=42225657
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CO11074347A CO6341484A2 (es) | 2008-11-25 | 2011-06-15 | Citoblastos para uso terapéutico que se derivan de monocitos humanos, y método para inducir los mismos |
Country Status (17)
Country | Link |
---|---|
US (2) | US9169463B2 (es) |
EP (1) | EP2365061A4 (es) |
JP (1) | JP5800505B2 (es) |
KR (1) | KR101682731B1 (es) |
CN (1) | CN102245757B (es) |
AR (1) | AR074406A1 (es) |
AU (1) | AU2009320881B2 (es) |
BR (1) | BRPI0921371A2 (es) |
CA (3) | CA2977820A1 (es) |
CO (1) | CO6341484A2 (es) |
IL (1) | IL212638A (es) |
MX (1) | MX336067B (es) |
RU (1) | RU2573906C2 (es) |
TW (1) | TWI539000B (es) |
UA (1) | UA110691C2 (es) |
WO (1) | WO2010061781A1 (es) |
ZA (1) | ZA201103268B (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102399741A (zh) * | 2010-09-19 | 2012-04-04 | 林雄斌 | 逆向分化体细胞产生造血干细胞的培养液、方法及用途 |
CN109952107A (zh) * | 2016-09-14 | 2019-06-28 | Tes控股股份有限公司 | Lin28a激活剂及其使用 |
CN107904202B (zh) * | 2017-11-22 | 2018-11-20 | 北京恩诺生物科技有限公司 | 一种制备多能干细胞样细胞的方法、组合物和应用 |
JP6375076B1 (ja) * | 2018-02-19 | 2018-08-15 | 株式会社 バイオミメティクスシンパシーズ | 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法 |
JP6574292B2 (ja) * | 2018-07-21 | 2019-09-11 | 株式会社 バイオミメティクスシンパシーズ | 間葉系幹細胞を用いたアトピー性皮膚炎治療における治療効果予測判定法 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4778787A (en) * | 1985-12-20 | 1988-10-18 | Trustees Of Boston University | Method for treatment of angina and myocardial infarctions with omental lipids |
US5272138A (en) * | 1988-02-12 | 1993-12-21 | The Biomembrane Institute | Naturally occurring gangliosides containing de-N-acetyl-sialic acid and their applications as modifiers of cell physiology |
US6084060A (en) * | 1996-12-09 | 2000-07-04 | Imclone Systems Incorporated | Composition and method for preserving progenitor cells |
DE19651443A1 (de) * | 1996-12-11 | 1998-06-18 | Hoechst Ag | Selbstverstärkende, pharmakologisch kontrollierbare Expressionssysteme |
EP0893493A3 (de) * | 1997-07-21 | 2002-12-04 | Aventis Pharma Deutschland GmbH | Genetisch veränderte Zellen und deren Verwendung in der Prophylaxe oder Therapie von Erkrankungen |
US20030157113A1 (en) * | 1999-12-28 | 2003-08-21 | Terman David S. | Compositions and methods for treatment of neoplastic disease |
DE10214095C1 (de) * | 2002-03-28 | 2003-09-25 | Bernd Karl Friedrich Kremer | Dedifferenzierte, programmierbare Stammzellen monozytären Ursprungs, sowie deren Herstellung und Verwendung |
TWI288779B (en) * | 2002-03-28 | 2007-10-21 | Blasticon Biotech Forschung | Dedifferentiated, programmable stem cells of monocytic origin, and their production and use |
WO2004087063A2 (en) | 2003-03-27 | 2004-10-14 | Janssen Pharmaceutica Nv | Use of erythropoietin in stroke recovery |
EP1694328A4 (en) * | 2003-12-02 | 2010-02-17 | Celgene Corp | METHOD AND COMPOSITIONS FOR THE TREATMENT AND SUPPLY OF HEMOGLOBINOPATHY AND ANEMIA |
US20050260748A1 (en) * | 2004-02-27 | 2005-11-24 | Michigan State University | Adult stem cells and uses thereof |
US8012752B2 (en) | 2006-12-29 | 2011-09-06 | Dow Agrosciences Llc | In vitro methods for the induction and maintenance of plant cell lines as single suspension cells with intact cell walls, and transformation thereof |
-
2009
- 2009-11-19 CA CA2977820A patent/CA2977820A1/en not_active Abandoned
- 2009-11-19 JP JP2010540461A patent/JP5800505B2/ja not_active Expired - Fee Related
- 2009-11-19 CA CA2977823A patent/CA2977823A1/en not_active Abandoned
- 2009-11-19 RU RU2011126165/10A patent/RU2573906C2/ru not_active IP Right Cessation
- 2009-11-19 CN CN200980146977.1A patent/CN102245757B/zh not_active Expired - Fee Related
- 2009-11-19 US US13/130,099 patent/US9169463B2/en not_active Expired - Fee Related
- 2009-11-19 EP EP09829029A patent/EP2365061A4/en not_active Withdrawn
- 2009-11-19 UA UAA201107956A patent/UA110691C2/uk unknown
- 2009-11-19 AU AU2009320881A patent/AU2009320881B2/en not_active Ceased
- 2009-11-19 MX MX2011005480A patent/MX336067B/es unknown
- 2009-11-19 CA CA2744289A patent/CA2744289A1/en not_active Abandoned
- 2009-11-19 BR BRPI0921371-6A2A patent/BRPI0921371A2/pt not_active IP Right Cessation
- 2009-11-19 KR KR1020117014559A patent/KR101682731B1/ko active IP Right Grant
- 2009-11-19 WO PCT/JP2009/069648 patent/WO2010061781A1/ja active Application Filing
- 2009-11-24 TW TW098139923A patent/TWI539000B/zh not_active IP Right Cessation
- 2009-11-25 AR ARP090104560A patent/AR074406A1/es unknown
-
2011
- 2011-05-03 IL IL212638A patent/IL212638A/en not_active IP Right Cessation
- 2011-05-05 ZA ZA2011/03268A patent/ZA201103268B/en unknown
- 2011-06-15 CO CO11074347A patent/CO6341484A2/es unknown
-
2015
- 2015-09-24 US US14/864,712 patent/US20160008434A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CN102245757B (zh) | 2014-11-26 |
AU2009320881B2 (en) | 2015-01-22 |
MX2011005480A (es) | 2011-06-20 |
UA110691C2 (uk) | 2016-02-10 |
US9169463B2 (en) | 2015-10-27 |
WO2010061781A1 (ja) | 2010-06-03 |
US20160008434A1 (en) | 2016-01-14 |
RU2573906C2 (ru) | 2016-01-27 |
TWI539000B (zh) | 2016-06-21 |
TW201024415A (en) | 2010-07-01 |
RU2011126165A (ru) | 2013-01-10 |
CA2744289A1 (en) | 2010-06-03 |
EP2365061A1 (en) | 2011-09-14 |
EP2365061A4 (en) | 2013-03-13 |
IL212638A0 (en) | 2011-07-31 |
JP5800505B2 (ja) | 2015-10-28 |
KR20110094084A (ko) | 2011-08-19 |
CA2977823A1 (en) | 2010-06-03 |
JPWO2010061781A1 (ja) | 2012-04-26 |
BRPI0921371A2 (pt) | 2014-11-18 |
AU2009320881A1 (en) | 2010-06-03 |
KR101682731B1 (ko) | 2016-12-05 |
AR074406A1 (es) | 2011-01-12 |
IL212638A (en) | 2017-08-31 |
ZA201103268B (en) | 2012-07-25 |
CA2977820A1 (en) | 2010-06-03 |
US20110223143A1 (en) | 2011-09-15 |
MX336067B (es) | 2016-01-06 |
CN102245757A (zh) | 2011-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO6341484A2 (es) | Citoblastos para uso terapéutico que se derivan de monocitos humanos, y método para inducir los mismos | |
CR11731A (es) | Composiciones y procedimientos para su preparación y uso | |
ME01199B (me) | Nove kompozicije adjuvanta | |
NO20075136L (no) | Nye liposompreparater | |
ECSP10010489A (es) | Nuevas formulaciones, comprimidos que comprenden tales formulaciones, su uso y procedimiento para su preparación | |
MX2011008340A (es) | Composición farmacéutica que comprende derivados de glucopiranosil difenilmetano, dosificación farmacéutica de la misma, procesos para su preparación y usos de la misma para el control glucemico mejorado en un paciente. | |
ECSP12011834A (es) | Composición farmacéutica, forma de dosificación farmacéutica, procedimiento para su preparación, métodos para su tratamiento y sus usos. | |
BR112012018132A2 (pt) | "marcadores de células - tronco tumorais e uso dos mesmos". | |
NI201200038A (es) | Conjugados de niacina y ácidos grasos y sus usos | |
BR112014031914A2 (pt) | cápsula de estradiol solúvel para inserção vaginal | |
HK1099508A1 (en) | X-ray and/or uv activatable particles, their preparation and their therapeutic or diagnostic uses | |
BR112012031727A2 (pt) | conjugado de droga-anticorpo, composição farmacêutica, uso do conjugado de droga-anticorpo, método para induzir a eliminação celular ou inibir o crescimento e/ou a proliferação de uma célula tumoral, e, método de tratamento de doença. | |
WO2009100137A3 (en) | Magnetic cells for localizing delivery and tissue repair | |
CL2007001648A1 (es) | Compuesto derivado de leptomicina; conjugado que comprende agente de unión a células unido a uno o mas de dichos derivados; composiciones farmacéuticas que comprenden dicho derivado o conjugado; util en el tratamiento del cancer; proceso de preparacion de un compuesto o de un conjugado de un derivado de leptomicina. | |
BR0211520A (pt) | Células apresentando antìgeno, método para preparação da mesma e uso da mesma para vacinas de câncer | |
BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
CU23632A1 (es) | Métodos para la identificación de candidatos terapéuticos contra enfermedades causadas por flavivirus y moléculas antivirales. | |
EP2952210A3 (en) | Compositions comprising saccharide binding moieties and methods for targeted therapy | |
WO2011035018A3 (en) | Suicide ready cells | |
UY33643A (es) | ?Conjugado cristalino de naloxol-PEG?. | |
Koczurkiewicz et al. | Triterpene saponosides from Lysimachia ciliata differentially attenuate invasive potential of prostate cancer cells | |
BR112012029995A2 (pt) | composição farmacêutica ou cosmética tópica útil para o tratamento de doenças ou condições que transcursam por meio de um déficit de maturação do envelope cornificado | |
CR20110226A (es) | Composición para tratar enfermedad | |
MX2015006370A (es) | Suplementos herbales y metodos para utilizar los mismos. | |
WO2014100857A8 (en) | Vaccines for the treatment of cancer and compositions for enhancing vaccine efficacy |